Company intelligence / Profile preview

Tarrex Biopharma

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Lead program TX803 has completed preclinical development and has FDA IND clearance to begin Phase 1 trials in colorectal cancer, particularly targeting RAS-mutant, anti-EGFR–resistant populations. Preclinical results showed good oral bioavailability, tolerability, and efficacy in animal tumor models including KRAS-mutant colorectal cancers[1][3].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

TX803

Unknown

Partnerships

Aranda Pharma

Beyond the preview

Go deeper on Tarrex Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tarrex Biopharma.

Explore the full profile